Otonomy Initiates Phase 3 Clinical Trial of OTIVIDEX™ in Ménière’s Disease
July 26, 2018 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, July 26, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced initiation...
Otonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
March 08, 2018 16:24 ET
|
Otonomy, Inc.
Type C meeting completed with FDA for OTIVIDEX™ in Ménière’s disease Consistent with prior guidance, pivotal trial for OTIVIDEX to start mid-2018 Conference call and webcast today at 4:30 p.m. EST ...
Otonomy to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update
March 01, 2018 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, March 01, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will...